The reaction of the pharmaceutical industry to the potentially groundbreaking decision by the United States to support a vaccine patent waiver in an effort to improve global supplies has never been the reaction of the pharmaceutical industry.
The pharmaceutical companies’ argument is this: innovation would be stifled, threatening the development of future treatments, and that would be disastrous for patients.
Do they have a point?
More about this article: Read More
This notice was published: 2021-05-06 20:30:13